Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.34 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLP1R | P43220 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20078727 | 0.90 | SIRT2 (0.34) | SIRT2SIRT1SIRT5SIRT3NPC1 | |
| SCHEMBL20197894 | 0.73 | SIRT2 (0.41) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL24774073 | 0.71 | KLKB1 (0.44) | SIRT2SIRT1SIRT5 | |
| SCHEMBL24860401 | 0.71 | HDAC1 (0.39) | SIRT2SIRT1SIRT5 | |
| SCHEMBL26273239 | 0.71 | SIRT2 (0.44) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL21781895 | 0.70 | SIRT2 (0.33) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL24164897 | 0.70 | FURIN (0.42) | SIRT2SIRT1SIRT5SIRT3 | |
| SCHEMBL20729911 | 0.69 | LMNA (0.36) | SIRT2SIRT1SIRT5SIRT3SMN1; SMN2 | |
| SCHEMBL21782008 | 0.69 | CHRNB2 (0.44) | SIRT2SIRT1 | |
| SCHEMBL25128878 | 0.68 | MMP2 (0.38) | SIRT2SIRT1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951141-B2 | Antibody-drug conjugates, their preparation and their therapeutic use | REGENERON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170121413-A1 | ANTIBODY-DRUG CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | REGENERON PHARMACEUTICALS, INC. | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121413-A1 | ANTIBODY-DRUG CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | CD22, CD47, CD2 | SIRT2 4451/4885SIRT1 4412/4885SIRT5 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.